Alibaba probe unearthed evidence it knowingly let dangerous drugs be sold to U.S. consumers

Chinese online retailer Alibaba and its U.S. payment processing affiliate allegedly allowed dangerous drugs, chemicals, and pill presses to be sold to American customers for eight years. This occurred despite internal warnings from employees about the company's compliance problems, according to public records.

The prolonged failure to prevent the sale of illicit and hazardous items highlights significant compliance shortcomings within Alibaba's operations. The company's platform served as a conduit for these dangerous goods to reach U.S. consumers, raising serious concerns about oversight and accountability.

Internal communications and records suggest that awareness of these compliance issues existed within the company, yet corrective actions were not sufficiently implemented or enforced. This inaction allowed the problematic sales to continue over an extended period, potentially endangering public health and safety in the United States.